INT2409

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1979
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.69
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (SCT) cellular_component (SCT)
Anatomy Link Frequency
smooth muscle 2
duodenum 1
stem cell 1
SCT (Homo sapiens)
Pain Link Frequency Relevance Heat
Cholecystokinin 26 100.00 Very High Very High Very High
dexamethasone 1155 98.26 Very High Very High Very High
corticosteroid 13 92.56 High High
Chronic pancreatitis 3 77.92 Quite High
Inflammation 8 72.20 Quite High
tetrodotoxin 2 57.76 Quite High
vincristine 9 53.20 Quite High
rheumatoid arthritis 2 45.60 Quite Low
Arthritis 2 40.24 Quite Low
cva 87 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Multiple Myeloma 528 99.60 Very High Very High Very High
Recurrence 27 95.60 Very High Very High Very High
Disease 175 94.64 High High
Rheumatic Diseases 5 87.60 High High
Exocrine Pancreatic Insufficiency 2 86.12 High High
Pancreatitis 3 77.92 Quite High
Cancer 49 77.44 Quite High
Pancreatic Cancer 3 75.00 Quite High
INFLAMMATION 7 72.20 Quite High
Nicotine Addiction 2 71.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
When gastric acid in the duodenum is not well-balanced by alkaline pancreatic secretions, it may induce a prolonged secretin stimulus which interacts with the pancreatic ductal cells resulting in an increased rate of ductular cell activity and turnover.
secretin Binding (interacts) of in duodenum
1) Confidence 0.48 Published 2005 Journal JOP Section Abstract Doc Link 15767727 Disease Relevance 0.67 Pain Relevance 0.26
The development, however, of de novo rheumatic disorders is being increasingly recognized following either autologous or allogeneic SCT procedures [4-6].
SCT Binding (recognized) of
2) Confidence 0.24 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2902413 Disease Relevance 0.24 Pain Relevance 0.05
This study compared the actions and interactions of human synthetic gastrin, octapeptide-cholecystokinin (OP-CCK), cholecystokinin (CCK), and secretin on the amplitude of isometric tension developed in strips of dog antral smooth muscle in vitro.
secretin Binding (interactions) of in smooth muscle associated with cholecystokinin
3) Confidence 0.16 Published 1979 Journal Am. J. Physiol. Section Abstract Doc Link 434148 Disease Relevance 0 Pain Relevance 0.41
Interaction between gastrin, CCK, and secretin on canine antral smooth muscle in vitro.
secretin Binding (Interaction) of in smooth muscle
4) Confidence 0.16 Published 1979 Journal Am. J. Physiol. Section Title Doc Link 434148 Disease Relevance 0 Pain Relevance 0.50
The combination of these agents with dexamethasone in particular has shown impressive activity in relapsed or refractory MM and adds to the wide range of therapeutic options available.45 Other options include conventional chemotherapy, melphalan plus prednisone, dexamethasone alone in good-risk patients and, in patients with early stem cell harvest, autologous SCT may be considered as salvage therapy.27
SCT Binding (salvage) of in stem cell associated with multiple myeloma and dexamethasone
5) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.62 Pain Relevance 0.18
Patients ineligible for SCT due to their age, performance status, comorbidities, or other factors have in the past received melphalan plus prednisone as the standard of care for induction therapy.38 However, other combinations have emerged, with the evidence base, in particular, supporting the combination of melphalan, prednisone, and thalidomide27,39 and most recently melphalan, prednisone, and bortezomib.40 Indeed, combination approaches with bortezomib as the first in class proteosome inhibitor, have shown particular promise both in autologous SCT eligible and nontransplantation populations, with high-quality responses seen.27 Other first-line options include melphalan, prednisone, and lenalidomide,41 lenalidomide plus dexamethasone,42,43 or dexamethasone plus thalidomide or bortezomib.39,44 The combination of lenalidomide and dexamethasone is now recognized by the National Comprehensive Cancer Network (NCCN) practice guidelines as an option for primary induction therapy in transplantation candidates based on category of evidence 2B (lower-level evidence including clinical experience and nonuniform consensus),27 together with bortezomib-based therapies.27

Relapsed or refractory disease

SCT Binding (ineligible) of associated with cancer, disease and dexamethasone
6) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.30 Pain Relevance 0.30
A total of 61% of patients enrolled in MM-009 and 55% of patients in MM-010 had previously received at least one prior SCT, and most had received ?
SCT Binding (received) of associated with multiple myeloma
7) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.87 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox